UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1386-1395

2017

Link zum Volltext

Verfügbarkeit prüfen

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Journal of the American College of Cardiology, 2014-06, Vol.63 (23), p.2541-2548

2014

Link zum Volltext

Verfügbarkeit prüfen

Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database

Acta orthopaedica, 2012-12, Vol.83 (6), p.653-660

2012

Link zum Volltext

Verfügbarkeit prüfen

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288

2014

Link zum Volltext

Verfügbarkeit prüfen

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

Circulation (New York, N.Y.), 2017-01, Vol.135 (4), p.338-351

2017

Link zum Volltext

Verfügbarkeit prüfen

Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies

Circulation (New York, N.Y.), 2017-05, Vol.135 (19), p.1819-1831

2017

Link zum Volltext

Verfügbarkeit prüfen

Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date

International journal of clinical practice (Esher), 2016-11, Vol.70 (11), p.886-897

2016

Link zum Volltext

Verfügbarkeit prüfen

Retrospective comparison of traditional and artificial intelligence-based heart failure phenotyping in a US health system to enable real-world evidence

BMJ open, 2023-08, Vol.13 (8), p.e073178-e073178

2023

Link zum Volltext

Verfügbarkeit prüfen

Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off‐treatment biopsy study

Journal of bone and mineral research, 2011-11, Vol.26 (11), p.2737-2744

2011

Link zum Volltext

Verfügbarkeit prüfen

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

Journal of the American Heart Association, 2017-10, Vol.6 (10), p.n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial

Clinical cardiology (Mahwah, N.J.), 2016-03, Vol.39 (3), p.137-144

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2016-04, Vol.315 (15), p.1580

2016

Link zum Volltext

Verfügbarkeit prüfen

Development and preliminary validation of a Function IndeX for Trauma (FIX-IT)

Canadian Journal of Surgery, 2013-10, Vol.56 (5), p.E114-E120

2013

Link zum Volltext

Verfügbarkeit prüfen

A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction

Cardiology and Therapy, 2020-12, Vol.9 (2), p.561-568

2020

Link zum Volltext

Verfügbarkeit prüfen

Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study

Journal of bone and joint surgery. American volume, 2020-08, Vol.102 (16), p.1416

2020

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

Journal of bone and joint surgery. American volume, 2020-04, Vol.102 (8), p.693

2020

Link zum Volltext

Verfügbarkeit prüfen

Evidence-based goals in LDL-C reduction

Clinical Research in Cardiology, 2017-04, Vol.106 (4), p.237-248

2017

Link zum Volltext

Verfügbarkeit prüfen

Healthcare Utilization and Statin Re‐Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction

Journal of the American Heart Association, 2018-05, Vol.7 (10), p.n/a

2018

Link zum Volltext

Verfügbarkeit prüfen

Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement

International journal of cardiology, 2016-12, Vol.225, p.184-196

2016

Link zum Volltext

Verfügbarkeit prüfen

Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date

International journal of clinical practice (Esher), 2016-11, Vol.70 (11), p.886-897

2016

Link zum Volltext

Verfügbarkeit prüfen

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance: The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab

Journal of the American College of Cardiology, 2014-06, Vol.63 (23), p.2541-2548

2014

Link zum Volltext

Verfügbarkeit prüfen

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials

Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 13797: Enabling Advanced Real-world Evidence in Heart Failure: A Pilot Study Defining Preferred Approaches to Electronic Health Record Data Use

Circulation (New York, N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A13797-A13797

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study

Journal of clinical lipidology, 2014-05, Vol.8 (3), p.335-336

2014

Link zum Volltext

Verfügbarkeit prüfen

A POOLED SAFETY ANALYSIS OF OVER 6000 PATIENTS FROM DOUBLE-BLIND AND OPEN-LABEL EXTENSION STUDIES WITH EVOLOCUMAB

Journal of the American College of Cardiology, 2016-04, Vol.67 (13), p.1865-1865

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(69)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(40)
Humans
(33)
Cardiovascular System & Cardiology
(23)
Cardiac & Cardiovascular Systems
(22)
Female
(21)
Male
(21)
Cardiology
(18)
Aged
(17)
Statins
(17)
Middle Aged
(15)
Adult
(13)
Antibodies, Monoclonal - Therapeutic Use
(13)
Cardiovascular
(13)
Cardiovascular Disease
(12)
Double-Blind Method
(11)
Hypercholesterolemia - Drug Therapy
(11)
Internal Medicine
(11)
Medicine
(11)
Pharmacology & Pharmacy
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies

Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date

Retrospective comparison of traditional and artificial intelligence-based heart failure phenotyping in a US health system to enable real-world evidence

Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off‐treatment biopsy study

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

Development and preliminary validation of a Function IndeX for Trauma (FIX-IT)

A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction

Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

Evidence-based goals in LDL-C reduction

Healthcare Utilization and Statin Re‐Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction

Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement

Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance: The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials

Abstract 13797: Enabling Advanced Real-world Evidence in Heart Failure: A Pilot Study Defining Preferred Approaches to Electronic Health Record Data Use

Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study

A POOLED SAFETY ANALYSIS OF OVER 6000 PATIENTS FROM DOUBLE-BLIND AND OPEN-LABEL EXTENSION STUDIES WITH EVOLOCUMAB

Suchergebnisse filtern